Haleos Labs Limi

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE320X01016
  • NSEID: HALEOSLABS
  • BSEID: 540679
INR
1,318.00
-33 (-2.44%)
BSENSE

Feb 11

BSE+NSE Vol: 508

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Medico Remedies
Everest Organics
Haleos Labs Limi
Trident Lifeline
Amanta Healthcar
Albert David
Jenburkt Pharma
Valiant Laborato
Zim Laboratories
Solara Active PP
Infinium Pharma

Why is Haleos Labs Limited ?

1
Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 9.15%
  • Poor long term growth as Net Sales has grown by an annual rate of 10.05% and Operating profit at 18.86% over the last 5 years
2
The company has declared positive results in Sep'2025 after 2 consecutive negative quarters
  • PBT LESS OI(Q) At Rs 8.07 cr has Grown at 203.38%
  • DEBT-EQUITY RATIO(HY) Lowest at 0.34 times
  • OPERATING PROFIT TO INTEREST(Q) Highest at 8.38 times
3
With ROCE of 11, it has a Attractive valuation with a 1.7 Enterprise value to Capital Employed
  • The stock is trading at a discount compared to its peers' average historical valuations
  • Over the past year, while the stock has generated a return of 2.21%, its profits have fallen by -14.5%
4
Majority shareholders : Promoters
5
Underperformed the market in the last 1 year
  • The stock has generated a return of 2.21% in the last 1 year, much lower than market (BSE500) returns of 13.00%
stock-recommendationReal-Time Research Report

Verdict Report

How much should you hold?

  1. Overall Portfolio exposure to Haleos Labs Limi should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Haleos Labs Limi for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Haleos Labs Limi
2.21%
0.04
57.91%
Sensex
10.41%
0.90
11.52%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
10.05%
EBIT Growth (5y)
18.86%
EBIT to Interest (avg)
3.25
Debt to EBITDA (avg)
2.65
Net Debt to Equity (avg)
0.33
Sales to Capital Employed (avg)
1.28
Tax Ratio
27.39%
Dividend Payout Ratio
3.96%
Pledged Shares
0
Institutional Holding
0.29%
ROCE (avg)
9.07%
ROE (avg)
8.63%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
21
Industry P/E
33
Price to Book Value
1.93
EV to EBIT
15.45
EV to EBITDA
10.26
EV to Capital Employed
1.70
EV to Sales
1.38
PEG Ratio
NA
Dividend Yield
0.11%
ROCE (Latest)
11.00%
ROE (Latest)
9.06%
Loading Valuation Snapshot...
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

13What is working for the Company
DEBT-EQUITY RATIO(HY)

Lowest at 0.34 times

OPERATING PROFIT TO INTEREST(Q)

Highest at 9.12 times

NET SALES(Q)

Highest at Rs 94.78 cr

PBDIT(Q)

Highest at Rs 14.05 cr.

PBT LESS OI(Q)

Highest at Rs 8.60 cr.

PAT(Q)

Highest at Rs 6.62 cr.

EPS(Q)

Highest at Rs 21.92

-1What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Loading Valuation Snapshot...

Here's what is working for Haleos Labs Limi

Operating Profit to Interest - Quarterly
Highest at 9.12 times
in the last five quarters
MOJO Watch
The company's ability to manage interest payments is improving

Operating Profit to Interest

Debt-Equity Ratio - Half Yearly
Lowest at 0.34 times and Fallen
each half year in the last five half yearly periods
MOJO Watch
The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Net Sales - Quarterly
Highest at Rs 94.78 cr
in the last five quarters
MOJO Watch
Near term sales trend is positive

Net Sales (Rs Cr)

Operating Profit (PBDIT) - Quarterly
Highest at Rs 14.05 cr.
in the last five quarters
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (Rs Cr)

Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 8.60 cr.
in the last five quarters
MOJO Watch
Near term PBT trend is positive

PBT less Other Income (Rs Cr)

Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 8.60 cr has Grown at 25.36%
Year on Year (YoY)
MOJO Watch
Near term PBT trend is positive

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly
Highest at Rs 6.62 cr.
in the last five quarters
MOJO Watch
Near term PAT trend is positive

PAT (Rs Cr)

Profit After Tax (PAT) - Quarterly
At Rs 6.62 cr has Grown at 21.0%
Year on Year (YoY)
MOJO Watch
Near term PAT trend is positive

PAT (Rs Cr)

Earnings per Share (EPS) - Quarterly
Highest at Rs 21.92
in the last five quarters
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (Rs)